文献速递腹部外周血管MR

原生与钆塞酸增强肝脏及脾脏T1 mapping无创诊断临床显著门脉高压的初步研究

Performance of native and gadoxetate-enhanced liver and spleen T1 mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results.
PubMed 文献 · Abdom Radiol (NY) · 2022-09-09

本研究纳入49例慢性肝病并接受HVPG测量和MRI的患者,评估原生T1、铁校正T1、钆塞酸二钠肝胆期T1 mapping及脾脏大小/体积和APRI对临床显著门脉高压(CSPH,HVPG≥10 mmHg)的诊断效能。结果显示肝脏T1-HBP、肝脏ΔT1和脾脏T1与HVPG显著相关,诊断CSPH的AUC分别为0.881、0.852和0.781,提示肝胆期T1 mapping有潜力用于无创诊断CSPH,但需进一步验证。

要点

  • 肝胆期肝脏T1 mapping诊断CSPH的AUC最高(0.881),优于脾脏T1和APRI。
  • 肝脏ΔT1与HVPG呈负相关(r=-0.437),肝胆期T1与HVPG正相关(r=0.543)。
  • 肝脏cT1、脾脏cT1和脾脏大小/体积与HVPG无显著相关性。
英文原文(摘要)· 点击展开

PURPOSE: In this preliminary study, our aim was to assess the utility of quantitative native-T1 (T1-pre), iron-corrected T1 (cT1) of the liver/spleen and T1 mapping of the liver obtained during hepatobiliary phase (T1-HBP) post-gadoxetate disodium, compared to spleen size/volume and APRI (aspartate aminotransferase-to-platelet ratio index) for noninvasive diagnosis of clinically significant portal hypertension [CSPH, defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg].

METHODS: Forty-nine patients (M/F: 27/22, mean age 53y) with chronic liver disease, HVPG measurement and MRI were included. Breath-held T1 and cT1 measurements were obtained using an inversion recovery Look-Locker sequence and a T2* corrected modified Look-Locker sequence, respectively. Liver T1-pre (n = 49), spleen T1 (obtained pre-contrast, n = 47), liver and spleen cT1 (both obtained pre-contrast, n = 30), liver T1-HBP (obtained 20 min post gadoxetate disodium injection, n = 36) and liver T1 uptake (ΔT1, n = 36) were measured. Spleen size/volume and APRI were also obtained. Spearman correlation coefficients were used to assess the correlation between each of liver/spleen T1/cT1 parameters, spleen size/volume and APRI with HVPG. ROC analysis was performed to determine the performance of measured parameters for diagnosis of CSPH.

RESULTS: There were 12/49 (24%) patients with CSPH. Liver T1-pre (r = 0.287, p = 0.045), liver T1-HBP (r = 0.543, p = 0.001), liver ΔT1 (r = - 0.437, p = 0.008), spleen T1 (r = 0.311, p = 0.033) and APRI (r = 0.394, p = 0.005) were all significantly correlated with HVPG, while liver cT1, spleen cT1 and spleen size/volume were not. The highest AUCs for the diagnosis of CSPH were achieved with liver T1-HBP, liver ΔT1 and spleen T1: 0.881 (95%CI 0.76-1.0, p = 0.001), 0.852 (0.72-0.98, p = 0.002) and 0.781 (0.60-0.95, p = 0.004), respectively.

CONCLUSION: Our preliminary results demonstrate the potential of liver T1 mapping obtained during HBP post gadoxetate disodium for the diagnosis of CSPH. These results require further validation.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Altinmakas, Bane, Hectors, et al. Performance of native and gadoxetate-enhanced liver and spleen T1 mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results. Abdom Radiol (NY). 2022. PMID: 36085378. doi:10.1007/s00261-022-03645-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。